BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22872444)

  • 1. Molecular characteristics of fibrolamellar hepatocellular carcinoma.
    Patonai A; Erdélyi-Belle B; Korompay A; Somorácz A; Törzsök P; Kovalszky I; Barbai T; Rásó E; Lotz G; Schaff Z; Kiss A
    Pathol Oncol Res; 2013 Jan; 19(1):63-70. PubMed ID: 22872444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Claudins and tricellulin in fibrolamellar hepatocellular carcinoma.
    Patonai A; Erdélyi-Belle B; Korompay A; Somorácz A; Straub BK; Schirmacher P; Kovalszky I; Lotz G; Kiss A; Schaff Z
    Virchows Arch; 2011 Jun; 458(6):679-88. PubMed ID: 21503766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational analysis of the p53 and K-ras genes and allelotype study of the Rb-1 gene for investigating the pathogenesis of combined hapatocellular-cholangiocellular carcinomas.
    Imai Y; Oda H; Arai M; Shimizu S; Nakatsuru Y; Inoue T; Ishikawa T
    Jpn J Cancer Res; 1996 Oct; 87(10):1056-62. PubMed ID: 8957064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unique genomic profile of fibrolamellar hepatocellular carcinoma.
    Cornella H; Alsinet C; Sayols S; Zhang Z; Hao K; Cabellos L; Hoshida Y; Villanueva A; Thung S; Ward SC; Rodriguez-Carunchio L; Vila-Casadesús M; Imbeaud S; Lachenmayer A; Quaglia A; Nagorney DM; Minguez B; Carrilho F; Roberts LR; Waxman S; Mazzaferro V; Schwartz M; Esteller M; Heaton ND; Zucman-Rossi J; Llovet JM
    Gastroenterology; 2015 Apr; 148(4):806-18.e10. PubMed ID: 25557953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updates in the diagnosis of combined hepatocellular-cholangiocarcinoma.
    Sciarra A; Park YN; Sempoux C
    Hum Pathol; 2020 Feb; 96():48-55. PubMed ID: 31931021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
    Hirsch TZ; Negulescu A; Gupta B; Caruso S; Noblet B; Couchy G; Bayard Q; Meunier L; Morcrette G; Scoazec JY; Blanc JF; Amaddeo G; Nault JC; Bioulac-Sage P; Ziol M; Beaufrère A; Paradis V; Calderaro J; Imbeaud S; Zucman-Rossi J
    J Hepatol; 2020 May; 72(5):924-936. PubMed ID: 31862487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrolamellar carcinoma: a review with focus on genetics and comparison to other malignant primary liver tumors.
    Ward SC; Waxman S
    Semin Liver Dis; 2011 Feb; 31(1):61-70. PubMed ID: 21344351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes.
    Xue R; Chen L; Zhang C; Fujita M; Li R; Yan SM; Ong CK; Liao X; Gao Q; Sasagawa S; Li Y; Wang J; Guo H; Huang QT; Zhong Q; Tan J; Qi L; Gong W; Hong Z; Li M; Zhao J; Peng T; Lu Y; Lim KHT; Boot A; Ono A; Chayama K; Zhang Z; Rozen SG; Teh BT; Wang XW; Nakagawa H; Zeng MS; Bai F; Zhang N
    Cancer Cell; 2019 Jun; 35(6):932-947.e8. PubMed ID: 31130341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature.
    Malouf GG; Job S; Paradis V; Fabre M; Brugières L; Saintigny P; Vescovo L; Belghiti J; Branchereau S; Faivre S; de Reyniès A; Raymond E
    Hepatology; 2014 Jun; 59(6):2228-37. PubMed ID: 24443104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrolamellar hepatocellular carcinoma: an immunohistochemical comparison with conventional hepatocellular carcinoma.
    Abdul-Al HM; Wang G; Makhlouf HR; Goodman ZD
    Int J Surg Pathol; 2010 Oct; 18(5):313-8. PubMed ID: 20444731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined hepatocellular and cholangiocellular carcinoma in a dog.
    Shiga A; Shirota K; Enomoto M
    J Vet Med Sci; 2001 Apr; 63(4):483-6. PubMed ID: 11346190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrolamellar carcinoma of the liver: a distinct entity within the hepatocellular tumors. A review.
    Vecchio FM
    Appl Pathol; 1988; 6(2):139-48. PubMed ID: 2839216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver.
    El Dika I; Bowman AS; Berger MF; Capanu M; Chou JF; Benayed R; Zehir A; Shia J; O'Reilly EM; Klimstra DS; Solit DB; Abou-Alfa GK
    Cancer; 2020 Sep; 126(18):4126-4135. PubMed ID: 32663328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive analysis of The Cancer Genome Atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma.
    Dinh TA; Vitucci EC; Wauthier E; Graham RP; Pitman WA; Oikawa T; Chen M; Silva GO; Greene KG; Torbenson MS; Reid LM; Sethupathy P
    Sci Rep; 2017 Mar; 7():44653. PubMed ID: 28304380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel diagnostic marker, p28GANK distinguishes hepatocellular carcinoma from potential mimics.
    Fu X; Tan L; Liu S; Li H; Chen L; Qin J; Wu M; Wang H
    J Cancer Res Clin Oncol; 2004 Sep; 130(9):514-20. PubMed ID: 15221469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging features of fibrolamellar hepatocellular carcinoma in gadoxetic acid-enhanced MRI.
    Palm V; Sheng R; Mayer P; Weiss KH; Springfeld C; Mehrabi A; Longerich T; Berger AK; Kauczor HU; Weber TF
    Cancer Imaging; 2018 Mar; 18(1):9. PubMed ID: 29490696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytogenetic aberrations in primary and recurrent fibrolamellar hepatocellular carcinoma detected by comparative genomic hybridization.
    Wilkens L; Bredt M; Flemming P; Kubicka S; Klempnauer J; Kreipe H
    Am J Clin Pathol; 2000 Dec; 114(6):867-74. PubMed ID: 11338475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1.
    Radwan NA; Ahmed NS
    Diagn Pathol; 2012 Oct; 7():149. PubMed ID: 23111165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary liver carcinoma arising in people younger than 30 years.
    Klein WM; Molmenti EP; Colombani PM; Grover DS; Schwarz KB; Boitnott J; Torbenson MS
    Am J Clin Pathol; 2005 Oct; 124(4):512-8. PubMed ID: 16146811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas.
    Somorácz A; Tátrai P; Horváth G; Kiss A; Kupcsulik P; Kovalszky I; Schaff Z
    Hum Pathol; 2010 Sep; 41(9):1310-9. PubMed ID: 20471664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.